dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Stradella, Agostina |
dc.contributor.author | Feliubadaló, Lídia |
dc.contributor.author | Grau Garces, Èlia |
dc.contributor.author | Velasco, Àngela |
dc.contributor.author | Balmaña Gelpí, Judith |
dc.contributor.author | Rofes, Paula |
dc.contributor.author | del Valle, Jesús |
dc.date.accessioned | 2021-04-08T10:53:28Z |
dc.date.available | 2021-04-08T10:53:28Z |
dc.date.issued | 2019-08 |
dc.identifier.citation | Stradella A, del Valle J, Rofes P, Feliubadaló L, Grau Garces E, Velasco A, et al. Does multilocus inherited neoplasia alleles syndrome have severe clinical expression? J Med Genet. 2019 Aug;56(8):521–5. |
dc.identifier.issn | 1468-6244 |
dc.identifier.uri | https://hdl.handle.net/11351/5830 |
dc.description | Síndromes de càncer; Panell genètic; Proves genètiques |
dc.description.sponsorship | Contract grant sponsor: Supported by the Carlos III National Health Institute and Ministerio de Educación y Ciencia funded by FEDER funds–a way to build Europe (PI16/00563, PI16/01363, SAF2015-68016-R and CIBERONC); the Government of Catalonia (Pla estratègic de recerca i innovació en salut (PERIS), 2017SGR1282 and 2017SGR496); and the scientific foundation Asociación Española Contra el Cáncer. |
dc.language.iso | eng |
dc.publisher | BMJ Publishing Group |
dc.relation.ispartofseries | Journal of Medical Genetics;56(8) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Gens del càncer |
dc.subject | Càncer - Prognosi |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Inheritance Patterns |
dc.title | Does multilocus inherited neoplasia alleles syndrome have severe clinical expression? |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/jmedgenet-2018-105700 |
dc.subject.decs | neoplasias |
dc.subject.decs | patrones de herencia |
dc.relation.publishversion | https://jmg.bmj.com/content/56/8/521.long |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | Stradella A] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. [del Valle J, Rofes P, Feliubadaló L] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Centro de Investigación Biomédica en RED (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. [Grau Garces È] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. [Velasco À] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain. [Balmaña-Gelpi J] Grup Alt Risc i Prevenció del Càncer, Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 30580288 |
dc.identifier.wos | 000478880800004 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00563 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F01363 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2015-68016-R |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |